The U.K. clinical cell-therapy pipeline continues to internationalize as manufacturing and scale-up collaborations expand. In one spotlight, iXCells Biotechnologies announced a multi-party effort with Rosebud Biosciences, Kantify and Incite to evaluate chemotherapeutic off-target toxicity using patient-specific organoids. The program will reprogram patient PBMCs into hiPSCs and differentiate them into heart, liver and kidney organoids, then quantify organ injury after exposure to investigational chemotherapies. The stated goal is to generate multi-organ toxicity profiles to reduce late-stage trial failures tied to unexpected off-target effects.